The AML Study Part 2

Start date

Jun 12th

Renumeration

$5,705

10 night stay, 2 appointments

Help Test a New Potential Treatment for Acute Myeloid Leukaemia

Acute Myeloid Leukemia (AML) is an aggressive cancer that disrupts normal blood and bone marrow function, with limited treatment options and a low five-year survival rate. This study explores a new investigational drug designed to target a specific protein, FLT3 kinase, which is involved in cancer growth in a significant number of AML cases. By inhibiting this protein, the treatment may slow or halt disease progression, offering hope for improved outcomes in AML therapy.

Apply Now

Schedule

Cohort 6

10 Night Clinic Stay

Check In

Jun 12th

Check Out

Jun 22nd

2 appointment

Jun 26th, Jul 03rd

To Qualify, You Must

Age

Be 18 to 55 years old

Gender

Be a healthy male or female (who isn't using hormonal contraceptives)

Physical Condition

NOT have any allergies to food or medications
Have NO significant medical conditions
NOT be a smoker (no tobacco/nicotine-containing products in the last 3 months)

Requirements

Have a BMI between 18.5 and 32kg/m2

Renumeration

$5705 * with Screening Reimbursement please see Terms

Help Test a New Potential Treatment for Acute Myeloid Leukaemia

Spots are limited. Find out if you qualify today!

Apply Now